Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010007/S028

IMMULITE Systems AFP

Siemens Healthcare Diagnostics, Inc. · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONP010007/S028

What did the FDA decide?

The FDA record for P010007/S028, under the title IMMULITE Systems AFP with decision OK30 dated 2026-09-22, is a 30-Day Notice whose supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. The stated change is to move manufacturing of a critical component within the same facility. The notice does not describe the component, its function, the affected manufacturing steps, or any validation or comparability data supporting the move.

The identifier P010007 ties this supplement to the original PMA for an alpha-fetoprotein kit for neural tube defects, product code LOK, with Siemens Healthcare Diagnostics, Inc. as applicant. It is a supplement notice concerning a manufacturing location change, not a new approval of the whole system, and the reported purpose does not by itself establish safety or clinical effectiveness. The record is silent on whether analytical performance or previously cleared indications are affected.

FDA approval order statement

to move manufacturing of a critical component within the same facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
Sep 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010007/S028
Regulatory pathway
PMA supplement
Product code
LOK
Decision code
OK30
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.

Product code
LOK
FDA device class
3

For the original device and its historical approval scope, see PMA P010007. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010007 · Original PMA

    IMMULITE/IMMULITE 1000 AFP AND IMMULITE 2000/IMMULITE 2500 AFP

  2. P010007/S028 received

    Application receipt date recorded by FDA.

  3. P010007/S028 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P010007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010007

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA approvalNov 9, 2001FDA
IMMULITE 2000 AFPP010007/S024
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 30, 2025FDA
IMMULITE 2000 AFPP010007/S025
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA
IMMULITE 2000 AFPP010007/S026
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA

Explore the linked device profile

Other records with product code LOK

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT LABORATORIESPMA supplementMay 11, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementMay 11, 2026FDA
ABBOTT LABORATORIESPMA supplementFeb 12, 2026FDA
BECKMAN COULTER, INC.PMA supplementNov 3, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
511 Benedict Ave., Tarrytown, NY, 10591

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records